Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Vaccine
; 31(40): 4389-97, 2013 Sep 13.
Article
em En
| MEDLINE
| ID: mdl-23856331
ABSTRACT
BACKGROUND:
This study (NCT00979602) evaluated the immunogenicity and relative protective efficacy of one dose of influenza A(H1N1)pdm09 vaccine with or without AS03 (an α-tocopherol oil-in-water emulsion based Adjuvant System).METHODS:
Four thousands and forty-eight healthy adults aged ≥ 18 years were randomized (11) to receive one dose of either the adjuvanted split virion (3.75 µg hemagglutinin antigen [HA]/AS03) or non-adjuvanted (15 µg HA) vaccine. Hemagglutination inhibition [HI] antibody response was evaluated before vaccination and at Days 21, 42 and 182 (Month 6). Safety of the study vaccines was evaluated during the entire study duration.RESULTS:
At Day 21, both study vaccines induced HI immune responses meeting the US regulatory criteria in subjects 18-64 years (seroprotection rate [SPR] 98.0% [97.1-98.6]; seroconversion rate [SCR] 89.7% [88.0-91.2] in the AS03-adjuvanted group; SPR 91.4% [89.9-92.8]; SCR 74.6% [72.3-76.9] in the non-adjuvanted group) and >64 years of age (SPR 86.0% [82.5-89.0]; SCR 75.3% [71.1-79.2] in the AS03-adjuvanted group; SPR 69.1% [64.6-73.3]; SCR 56.7% [52.0-61.3] in the non-adjuvanted group). The AS03-adjuvanted vaccine induced higher HI geometric mean titers than the non-adjuvanted vaccine at all time points. At Month 6, only subjects 18-64 years of age from both vaccine groups still met the US regulatory criteria (SPR 82.1% [80.0-84.1]; SCR 62.3% [59.6-64.8] in the AS03-adjuvanted group; SPR 75.3% [72.9-77.5]; SCR 53.7% [51.0-56.4] in the non-adjuvanted group). Protective efficacy was not evaluated due to low number of RT-qPCR-confirmed A(H1N1)pdm09 influenza cases. Through Month 12, 216 serious adverse events (in 157subjects:
84 in the AS03-adjuvanted and 73 in the non-adjuvanted group) and 12 potentially immune mediated diseases (5 in the AS03-adjuvanted and 7 in the non-adjuvanted group) were reported.CONCLUSION:
A single dose of either adjuvanted or non-adjuvanted influenza A(H1N1)pdm09 vaccine induced protective HI antibody levels against the A/California/7/2009 strain that persisted through Month 6 in the 18-64 years population.Palavras-chave
ATP; Adjuvant; BARDA; BMI; Biomedical Advanced Research and Development Authority; CBER; CHMP; CI; Center for Biologics Evaluation & Research; Committee for Medicinal Products for Human Use; GMFR; GMT; H1N1; HA; HHS; HI; ILIs; Influenza; Influenza-Like-Illnesses; Pandemic; RVP; SAEs; SCR; SD; SPR; TVC; United States Department of Health and Human Services; VEI; Vaccine; WHO; World Health Organization; according to protocol; body mass index; confidence interval; geometric mean fold rise; geometric mean titer; hemagglutination inhibition; hemagglutinin; pIMDs; potential immune mediated diseases; respiratory viral panel; serious adverse events; seroconversion rate; seroprotection rate; standard deviation; total vaccinated cohort; vaccine effectiveness improvement
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esqualeno
/
Vacinas contra Influenza
/
Adjuvantes Imunológicos
/
Alfa-Tocoferol
/
Influenza Humana
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article